financetom
Business
financetom
/
Business
/
Hewlett Packard Enterprise Third-Quarter Earnings Unexpectedly Rise; Revenue Tops Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hewlett Packard Enterprise Third-Quarter Earnings Unexpectedly Rise; Revenue Tops Views
Sep 6, 2024 12:38 PM

04:41 PM EDT, 09/04/2024 (MT Newswires) -- Hewlett Packard Enterprise ( HPE ) late Wednesday reported a surprise increase in fiscal third-quarter earnings while the company's revenue came in stronger than expected.

Adjusted per-share earnings rose to $0.50 during the quarter ended July 31 from $0.49 a year earlier. The consensus on Capital IQ had called for a drop to $0.47. Revenue grew 10% to $7.71 billion, above Wall Street's $7.67 billion view.

Server revenue climbed 35% year over year to $4.28 billion. The intelligent edge division declined 23% to $1.12 billion, while hybrid cloud sales fell 7% to $1.3 billion.

Hewlett Packard ( HPE ) forecasts full-year adjusted EPS between $1.92 and $1.97, compared with the prior $1.85 and $1.95 range. It continues to expect fiscal 2024 revenue to grow by 1% to 3% on a constant currency basis. The consensus on Capital IQ is for normalized EPS of $1.92 and revenue of $29.72 billion.

For the fourth quarter, Hewlett Packard ( HPE ) expects adjusted EPS to be in the range of $0.52 to $0.57 and revenue between $8.1 billion and $8.4 billion. Analysts are estimating $0.55 and $8.15 billion, respectively.

The stock was declining 4.2% in after-hours trade.

Price: 17.98, Change: -0.79, Percent Change: -4.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ParaZero Receives Initial Order for Counter Drone Solution
ParaZero Receives Initial Order for Counter Drone Solution
Sep 13, 2024
11:03 AM EDT, 09/13/2024 (MT Newswires) -- ParaZero Technologies ( PRZO ) said Friday it received an initial order for its Counter Unmanned Aerial Systems solution from an undisclosed global defense client. The C-UAS solution leverages ParaZero's ( PRZO ) proprietary technology to provide an advanced platform for countering threats from rogue or hostile drones, the company said. Shares of...
Bitfarms Signs Deal With Stronghold Digital Mining's Unit to Deploy Bitmain T21 Miners in Pennsylvania
Bitfarms Signs Deal With Stronghold Digital Mining's Unit to Deploy Bitmain T21 Miners in Pennsylvania
Sep 13, 2024
11:04 AM EDT, 09/13/2024 (MT Newswires) -- Bitfarms ( BITF ) said Friday it has signed a miner hosting agreement with Stronghold Digital Mining's ( SDIG ) Stronghold Digital Mining Hosting unit to deploy 10,000 Bitmain T21 miners at the latter's Panther Creek facility in Pennsylvania. The company anticipates energization in October and will bring 2.2 EH/s online. The agreement...
Factbox-Boeing strike puts spotlight on 737 MAX customers waiting for deliveries
Factbox-Boeing strike puts spotlight on 737 MAX customers waiting for deliveries
Sep 13, 2024
(Reuters) - Boeing's ( BA ) West Coast factory workers walked off the job early on Friday after they unanimously rejected a contract, halting production of the company's best-selling 737 MAX jet. The planemaker has more than 4,700 of the jets on order, with Southwest Airlines ( LUV ), United Airlines, and Lion Air the top three customers awaiting deliveries,...
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data
Sep 13, 2024
11:07 AM EDT, 09/13/2024 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Friday that initial data from an ongoing phase 1 clinical trial of small molecule degrader candidate CFT1946 targeting BRAF V600 mutations in solid tumors is well tolerated at all doses and there were no dose-limiting toxicities. Mild to bothersome adverse events occurred in over 10% of patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved